Blueshift Asset Management LLC Has $1.81 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Blueshift Asset Management LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 652.1% in the 3rd quarter, Holdings Channel reports. The firm owned 26,955 shares of the medical device company’s stock after buying an additional 23,371 shares during the quarter. Blueshift Asset Management LLC’s holdings in DexCom were worth $1,807,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom during the 2nd quarter worth about $25,000. Sachetta LLC lifted its holdings in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares during the last quarter. DT Investment Partners LLC boosted its position in shares of DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the period. Riverview Trust Co grew its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the last quarter. Finally, ORG Partners LLC lifted its stake in shares of DexCom by 1,992.0% in the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock valued at $59,000 after buying an additional 498 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock worth $399,319 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Price Performance

DXCM opened at $77.94 on Wednesday. The stock has a market cap of $30.44 billion, a P/E ratio of 46.67, a P/E/G ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a fifty day simple moving average of $70.94 and a 200 day simple moving average of $88.58.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Stifel Nicolaus upped their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Royal Bank of Canada lowered their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein increased their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. JPMorgan Chase & Co. boosted their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Wells Fargo & Company raised their target price on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.